Glaukos (NYSE:GKOS) Reaches New 12-Month Low - Should You Sell?

Key Points

• Glaukos Corporation reached a new 52-week low during trading at $75.36, with its stock last trading at $77.64 after previously closing at $87.17.
• Analyst ratings for Glaukos vary, with one Strong Buy, eleven Buy, two Hold, and two Sell ratings, reflecting a consensus target price of $116.92.
• The company reported a quarterly revenue of $124.12 million, exceeding expectations, and a narrower loss per share of ($0.24), compared to ($0.52) a year prior.

Glaukos Corporation (NYSE:GKOS - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $75.36 and last traded at $77.64, with a volume of 1272812 shares trading hands. The stock had previously closed at $87.17.

Wall Street Analyst Weigh In

GKOS has been the subject of several research reports. William Blair raised shares of Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Zacks Research cut Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. UBS Group raised their price objective on Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Wells Fargo & Company raised their price objective on Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group started coverage on Glaukos in a research note on Wednesday, October 1st. They set a "buy" rating and a $103.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $116.92.

Glaukos Stock Performance

The company's 50 day moving average price is $87.74 and its 200-day moving average price is $92.21. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The company has a market cap of $4.56 billion, a PE ratio of -48.17 and a beta of 0.76.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. During the same period in the previous year, the business posted ($0.52) EPS. The firm's quarterly revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in Glaukos by 133.9% in the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 158 shares during the period. First Horizon Advisors Inc. raised its stake in Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 159 shares during the period. Park Place Capital Corp grew its holdings in Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 162 shares in the last quarter. AlphaQuest LLC grew its holdings in Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier's stock valued at $67,000 after buying an additional 633 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 136 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.